PLIANT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20[•] Subordinated Debt SecuritiesIndenture • July 2nd, 2021 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of [•], 20[•], among PLIANT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [TRUSTEE] as trustee (the “Trustee”):
PLIANT THERAPEUTICS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • July 2nd, 2021 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • New York
Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 5th, 2022 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of May 4, 2022 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time, including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and PLIANT THERAPEUTICS, INC., a Delaware corporation with offices located at 260 Littlefield Avenue, S San Francisco CA 94080 (“Borrower”), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
PLIANT THERAPEUTICS, INC. [FORM OF] DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENTIndemnification Agreement • May 11th, 2020 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [________] by and between Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), and [_____] (“Indemnitee”).
SUMMARY OF BASIC LEASE INFORMATIONLease • May 11th, 2020 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • California
BRITANNIA OYSTER POINT LEASELease • October 3rd, 2023 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • California
This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between HCP BTC, LLC, a Delaware limited liability company ("Landlord"), and PLIANT THERAPEUTICS, INC., a Delaware corporation ("Tenant").
Pliant Therapeutics, Inc. [●] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • May 26th, 2020 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • New York
Pliant Therapeutics, Inc. 8,333,334 Shares Common Stock (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • January 25th, 2023 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • New York
Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities”; the Option Securities, collectively with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEENCollaboration and License Agreement • May 11th, 2020 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (this "Agreement") is made as of October 17, 2019 (the "Execution Date"), by and between Novartis Institutes for Biomedical Research, Inc., a corporation organized and existing under the laws of the State of Delaware, located at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 ("NVS") and Pliant Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware, located at 260 Littlefield Avenue, South San Francisco, CA 94080 ("Pliant"). NVS and Pliant are each referred to individually as a "Party" and together as the "Parties."
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 6th, 2024 • Pliant Therapeutics, Inc. • Pharmaceutical preparations
may from time to time be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of March 11, 2024 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time, including Oxford in its capacity as a Lender, OXFORD FINANCE CREDIT FUND II LP, by its manager Oxford Finance Advisors, LLC, and OXFORD FINANCE CREDIT FUND III LP, by its manager Oxford Finance Advisors, LLC, each with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (each a “Lender” and collectively, the “Lenders”), and PLIANT THERAPEUTICS, INC., a Delaware corporation with offices located at 260 Littlefield Avenue, S San Francisco CA 94080 (“Borrower”), and provides the t
ContractCollaboration and License Agreement • March 9th, 2023 • Pliant Therapeutics, Inc. • Pharmaceutical preparations
TERMINATION AGREEMENTTermination Agreement • October 3rd, 2023 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • California
This Termination Agreement (this "Agreement") is entered into as of September _28 , 2023, by and between HEALTHPEAK OP, LLC, a Maryland limited liability company (successor-interest to HCP, Inc., and referred to herein as "Landlord"), and PLIANT THERAPEUTICS, INC., a Delaware corporation ("Tenant").
PLIANT THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 19, 2019Investors’ Rights Agreement • March 16th, 2020 • Pliant Therapeutics, Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of December, 2019, by and among PLIANT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, (together with any subsequent investors who become parties hereto as “Investors” in accordance with Section 6.9 hereto, collectively, the “Investors”).
EAST\196098002.6 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of October 4, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an...Loan and Security Agreement • March 9th, 2023 • Pliant Therapeutics, Inc. • Pharmaceutical preparations
